- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gilead Sciences Inc (GILD)Gilead Sciences Inc stock price live, this page displays NASDAQ GILD stock exchange data. View the GILD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Gilead Sciences Inc real time stock price chart below.
What Is the Gilead Sciences Inc Stock Price Today?
The Gilead Sciences Inc stock price today is 93.53.
What Is the Stock Symbol for Gilead Sciences Inc?
The stock symbol for Gilead Sciences Inc is ""GILD.""
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the NASDAQ stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead Sciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GILD quote. (ISIN: US3755581036)
What Is the Gilead Sciences Inc Stock Price Today?
The Gilead Sciences Inc stock price today is 93.53.
What Is the Stock Symbol for Gilead Sciences Inc?
The stock symbol for Gilead Sciences Inc is ""GILD.""
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the NASDAQ stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead Sciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GILD quote. (ISIN: US3755581036)
93.38
+1.79(+1.95%)
Closed
After Hours
93.390.00(0.00%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
91.73
94.27
52 wk Range
62.07
98.90
GILD Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
91.7394.27
52 wk Range
62.0798.90
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
Unlock(3.36%)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
Unlock(3.36%)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockGILD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
97.85
Upside
+4.62%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
16 analysts have revised their earnings upwards for the upcoming period
- Gilead Sciences CFO sells $23 million in stock
- Investing.com
- Gilead, Tubulis sign ADC development agreement
- Investing.com
- Gilead Sciences CFO sells $23 million in stock
- Investing.com
- Gilead, Tubulis sign ADC development agreement
- Investing.com
- Is Trump 2.0 good or bad for healthcare stocks?
- Investing.com
Pro
Gilead Sciences Inc Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences Inc SWOT Analysis
HIV Market Dominance | Gilead's HIV franchise, led by Biktarvy, continues to drive strong financial performance with potential expansion through innovative treatments like lenacapavi |
Pipeline Progress | Explore Gilead's promising pipeline, including lenacapavir for HIV prevention and a new oral GLP-1 obesity treatment, signaling potential for diversified growth |
Competitive Challenges | Delve into Gilead's strategic navigation of competitive pressures in oncology and HCV segments, and the impact on its market position |
Financial Outlook | Analyst price targets range from $72 to $95, reflecting varied perspectives on Gilead's growth potential amid core strengths and emerging challenges |
GILD Full Pro Research
Institutional-Grade Stock Analysis
Understand how GILD earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Gilead Sciences Inc Earnings Call Summary for Q2/2024
- Q1 product sales up 6% YoY to $6.1B, excluding Veklury; HIV sales +4%, oncology +18%
- Trodelvy sales exceed $300M, up 39% YoY; cell therapy sales reach $480M
- Full-year revenue outlook unchanged: $27.1B-$27.5B product sales (ex-Veklury)
- Non-GAAP EPS would be $1.82, higher than expected, excluding tax-impacted items
- Seladelpar FDA decision expected in August; optimistic about Anito-cel potential
Last Updated: 29/04/2024, 23:44
Read Full TranscriptCompare GILD to Peers and Sector
Metrics to compare | GILD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGILDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 925.6x | −1.6x | −0.7x | |
PEG Ratio | −9.25 | −0.01 | 0.00 | |
Price/Book | 6.3x | 1.4x | 2.6x | |
Price / LTM Sales | 4.1x | 6.2x | 3.2x | |
Upside (Analyst Target) | 5.9% | 453.3% | 45.9% | |
Fair Value Upside | Unlock | 26.7% | 7.6% | Unlock |
Analysts' Recommendations
19 Buy
12 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 97.85
(+4.79% Upside)
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.101
Dividend Yield
3.36%
Industry Median 1.74%
Annualised payout
3.0800
Paid quarterly
5-Years Growth
+4.46%
Growth Streak
People Also Watch
FAQ
What Is the Gilead (GILD) Premarket Price Today?
The Gilead (GILD) premarket price is . Premarket price change units: . Premarket percentage change: . Premarket volume: . Current date: 05 Dec 2024. Previous close: 91.59
What Stock Exchange Does Gilead Trade On?
Gilead is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Gilead?
The stock symbol for Gilead is "GILD."
What Is the Gilead (GILD) Afterhours Price Today? (Afterhours variable test: ) Current Date: 05 Dec 2024
After hours price: . After hours price change (units): . Price change percentage:
What Is the Gilead Market Cap?
As of today, Gilead market cap is 116.36B.
What is Gilead Earnings Per Share?
The Gilead EPS is 0.101.
What Is the Next Gilead Earnings Date?
Gilead will release its next earnings report on 10 Feb 2025.
From a Technical Analysis Perspective, Is GILD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Is Gilead (GILD) Price Target According to Analysts?
Based on analysts, the average 12-month price target for Gilead is , with a high estimate of and a low estimate of . analysts recommend buying the stock, while suggest selling, leading to an overall rating of . The stock has an upside potential of %.
What Is Gilead (GILD) Price Target According to Analysts?
Based on analysts, the average 12-month price target for Gilead is , with a high estimate of and a low estimate of . analysts recommend buying the stock, while suggest selling, leading to an overall rating of . The stock has an upside potential of %.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.